Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Keiko Murase"'
Autor:
Michiko Imamura, Takashi Morimoto, Takashi Nomura, Shintaro Michishita, Arisa Nishimukai, Tomoko Higuchi, Yukie Fujimoto, Yoshimasa Miyagawa, Ayako Kira, Keiko Murase, Kazuhiro Araki, Yuichi Takatsuka, Koshi Oh, Yoshikazu Masai, Kouhei Akazawa, Yasuo Miyoshi
Publikováno v:
World Journal of Surgical Oncology, Vol 16, Iss 1, Pp 1-11 (2018)
Abstract Background Although the prognosis for operable breast cancers is reportedly worse if serum carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) levels are above normal, the usefulness of this prognosis is limited due to the low se
Externí odkaz:
https://doaj.org/article/5a6e30eea34e484e8a64a217e128c415
Autor:
Yusa Atake, Masayuki Nagahashi, Haruka Kanaoka, Akira Hattori, Ayako Bun, Reiko Fukui, Hiromi Ozawa, Yukie Fujimoto, Tomoko Higuchi, Michiko Imamura, Keiko Murase, Yuichi Takatsuka, Mina Kashima, Chiho Okada, Chinatsu Kinjo, Mikako Miyata, Ayako Miyazaki, Mako Ueda, Hiroshi Tsubamoto, Hideaki Sawai, Yasuo Miyoshi
Publikováno v:
Cancer Research. 83:P5-12
Background: The usefulness of prophylactic surgery and surveillance for hereditary breast cancer has been demonstrated, and germline testing for BRCA1 and BRCA2 had been covered by insurance since 2020 in Japan. In addition to BRCA1 and BRCA2, severa
Autor:
Haruka, Kanaoka, Masayuki, Nagahashi, Yusa, Atake, Akira, Hattori, Ayako, Bun, Reiko, Fukui, Hiromi, Ozawa, Yukie, Fujimoto, Tomoko, Higuchi, Keiko, Natori, Michiko, Imamura, Keiko, Murase, Yuichi, Takatsuka, Yasuo, Miyoshi
Publikováno v:
Anticancer Research. 42:4867-4878
The aim of this study was to elucidate the clinical significance of peripheral blood biomarkers, including absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and C-reactive protein (CRP) in patie
Autor:
Yosuke Nishiura, Keisuke Ota, Toshie Kobayashi, Akane Kurachi, Keiko Murase, Masataka Ishiguro, Tsuyako Hirano, Yuichi Ito, Atsuki Ide, Takayuki Hamano
Publikováno v:
Nihon Toseki Igakkai Zasshi. 55:215-220
Publikováno v:
In Talanta 15 June 2011 84(5):1205-1208
Autor:
Masaru Miyashita, Michiko Imamura, Kazuhiko Yamagami, Mayuko Miki, Toshitaka Okuno, Shintaro Takao, Hirofumi Suwa, Muneharu Konishi, Yasuo Miyoshi, Yasushi Shigeoka, Koichi Hirokaga, Keiko Murase, Hirokazu Tanino, Ayako Yanai
Publikováno v:
Anticancer research. 41(6)
Background/aim S-1, a 5-fluorouracil(5-FU) oral anti-cancer drug, has been traditionally used with a schedule of 4-week oral administration followed by 2-week rest for breast cancer treatment. We, herein, aimed to investigate the clinical efficacy an
Autor:
Yuichi Takatsuka, Yukie Fujimoto, Arisa Nishimukai, Michiko Imamura, Yasuo Miyoshi, Yoshimasa Miyagawa, Keiko Murase, Tomoko Higuchi, Ayako Yanai
Publikováno v:
Cancer Research. 77:P2-05
Background: It has been well demonstrated that patients who achieved pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) had a favorable prognosis compared with patients who did not (non-pCR). Even though pCR was not attained, r
Autor:
Yoshimasa Miyagawa, Keiko Murase, Arisa Nishimukai, Hiromi Ozawa, Tomoko Higuchi, Kazuhito Fukushima, Yukie Fujimoto, Ayako Yanai, Yasuo Miyoshi, Kazuhiro Kitajima, Michiko Imamura, Yuichi Takatsuka
Publikováno v:
The Breast. 30:5-12
Adjuvant treatments for operable breast cancers are determined according to subtypes defined based on estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) status. The ER+/HER2− subtype can be divided into luminal A and luminal
Autor:
Muneharu Konishi, Y Shigeoka, Hirofumi Suwa, Yasuo Miyoshi, Shintaro Takao, Kazuhiko Yamagami, Keiko Murase, Ayako Yanai, Mayuko Miki, Masayuki Imamura, Masaru Miyashita, Toshitaka Okuno, K. Hirokaga, Kohei Akazawa
Publikováno v:
Annals of Oncology. 30:ix17-ix18
Background When considering treatment for metastatic and recurrent breast cancer, it is necessary to select drugs with emphasis on side effects and QOL. In Japan, oral 5-FU drugs have often been used for initial treatment. In the conventional schedul
Autor:
Yasuo Miyoshi, Yuichi Takatsuka, Yoshimasa Miyagawa, Keiko Murase, Tomoko Higuchi, Ayako Yanai, Michiko Imamura, Arisa Nishimukai, Hiromi Ozawa
Publikováno v:
Cancer Research. 76:P6-16
Background: Bone-modifying agents have demonstrated their efficacy for treatment by suppressing osteoclast function. The activity of bone-modifying agents can be monitored by means of bone resorption markers such as c-terminal crosslinking telopeptid